REGN Q4 2022 Earnings Report — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

Regeneron Pharmaceuticals, Inc.REGN

Q4 2022 Earnings

Reported February 6, 2023

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q4 2022	Q3 2022	Q4 2021	QoQ Change	YoY Change
Revenue	$3.4B	$2.9B	$5.0B	16.3%	-31.0%
Op. Income	$1.3B	$1.2B	$2.6B	7.5%	-50.2%
Gross Margin	85.2%	86.0%	78.7%	-0.9pp	6.5pp
Net Margin	35.1%	44.8%	45.0%	-9.7pp	-10.0pp
EPS (Diluted)	$10.50	$11.66	$19.69	-9.9%	-46.7%
Free Cash Flow	$1.6B	$486M	$2.2B	222.3%	-29.3%

Revenue Flow

Item	Amount
REVENUE	$3.4B
Cost of Revenue	$507M
GROSS PROFIT	$2.9B
R&D Expenses	$942M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$657M
Other Expenses	-$7M
Operating Expenses	$1.6B
Cost & Expenses	$2.1B
OPERATING INCOME	$1.3B
Interest Income	$0
Interest Expense	$17M
Other Income/Expenses	$9M
INCOME BEFORE TAX	$1.3B
Income Tax Expense	$128M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$100M
EBIT	$1.3B
EBITDA	$1.4B
EPS	$11
EPS Diluted	$11

Income Statement

Item	Amount
REVENUE	$3.4B
Cost of Revenue	$507M
GROSS PROFIT	$2.9B
R&D Expenses	$942M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$657M
Other Expenses	-$7M
Operating Expenses	$1.6B
Cost & Expenses	$2.1B
OPERATING INCOME	$1.3B
Interest Income	$0
Interest Expense	$17M
Other Income/Expenses	$9M
INCOME BEFORE TAX	$1.3B
Income Tax Expense	$128M
Net Income from Continuing Ops	$1.2B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$1.2B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$1.2B
D&A	$100M
EBIT	$1.3B
EBITDA	$1.4B
EPS	$11
EPS Diluted	$11

Cash Flow Statement

Item	Amount
Net Income	$1.2B
Depreciation & Amortization	$100M
Stock-Based Compensation	$232M
Deferred Income Tax	-$280M
Other Non-Cash Items	$88M
Change in Working Capital	$382M
OPERATING CASH FLOW	$1.7B
Capital Expenditure	-$152M
Acquisitions (Net)	$1.6B
Purchases of Investments	-$3.1B
Sales/Maturities of Investments	$1.5B
Other Investing Activities	-$1.7B
NET CASH FROM INVESTING	-$1.9B
Net Debt Issuance	$0
Common Stock Repurchased	-$620M
Common Dividends Paid	$0
Other Financing Activities	-$189M
NET CASH FROM FINANCING	-$248M
FREE CASH FLOW	$1.6B
Net Change in Cash	-$385M

Balance Sheet

Item	Amount
Cash & Equivalents	$3.1B
Short-Term Investments	$4.6B
Net Receivables	$5.3B
Inventory	$2.4B
Other Current Assets	$0
TOTAL CURRENT ASSETS	$15.9B
PP&E (Net)	$3.8B
Goodwill	$0
Intangible Assets	$916M
Long-Term Investments	$6.6B
Tax Assets	$1.7B
Other Non-Current Assets	$336M
TOTAL NON-CURRENT ASSETS	$13.3B
TOTAL ASSETS	$29.2B
Account Payables	$589M
Short-Term Debt	$0
Deferred Revenue	$478M
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$3.1B
Long-Term Debt	$2.0B
Deferred Revenue NC	$70M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$638M
TOTAL NON-CURRENT LIABILITIES	$3.4B
TOTAL LIABILITIES	$6.6B
Common Stock	$100.0K
Additional Paid-In Capital	$9.9B
Retained Earnings	$23.3B
Treasury Stock	-$10.4B
Accum. Other Comp. Income	-$239M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$22.7B
Minority Interest	$0
TOTAL EQUITY	$22.7B
TOTAL LIABILITIES & EQUITY	$29.2B
Total Debt	$2.7B
Net Debt	-$405M